Diabetes(Oral Hypoglycemic Agents)

Diabetes(Oral Hypoglycemic Agents)


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
Payment Terms
Negotiable
Production method
Negotiable
Shipping / Lead Time
Negotiable / Negotiable
Keyword
Category
Other Pharmaceutical Chemicals
tK Meet
tK Meet

Apply a video call to the Supplier

SEND TO SUPPLIER INQUIRY

Myungmoon Pharm. Co., Ltd.

Country / Year Established
South Korea South Korea /
Business type
Others
Verified Certificate

16

TRADE TOWER

DUNS

Product name Diabetes(Oral Hypoglycemic Agents) Certification -
Category Other Pharmaceutical Chemicals Ingredients -
Keyword - Unit Size -
Brand name - Unit Weigh -
origin Stock -
Supply type - HS code -

Product Information

Mepiril Tab.(Glimepiride 2mg)

Composition : One tablet contains
Glimepiride - 2mg

Indication & Usage : noninsulin-dependent (Type II) diabetes mellitus (NIDDM)

  • MEPIRIL is indicated for the treatment of type 2 diabetes mellitus, when diet, physical exercise and weight reduction alone are not adequate.
  • Refer to insert-paper for further information.

Dosage & Administration :

  • Dosage is determined by the results of blood and urinary glucose determinations.
  • The starting dose is 1 mg glimepiride per day. If control is unsatisfactory the dosage should be increased, based on the glycaemic control, in a stepwise manner with an interval of about 1 to 2 weeks between each step, to 2, 3 or 4 mg glimepiride per day.
  • A dosage of more than 4mg glimepiride per day gives better results only in exceptional cases. The maximum recommended dose is 6mg glimepiride per day.

Package : 100, 500 Tablets

 
Metiben Tab. 500/5mg(Metformin HCL 500mg, Glibenclamide 5mg)
Metiben Tab. 500/2.5mg(Metformin HCL 500mg, Glibenclamide 2.5mg)

Composition : One tablet contains
Metformin.HCI - 500mg
Glibenclamide - 5/2.5mg

Indication & Usage :

  • METIBEN is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.
  • METIBEN is indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.

Dosage & Administration

  • The recommended starting dose is 500/2.5 mg once a day with a meal.
  • The maximum recommended daily dose is 2,000 mg metformin / 20 mg glyburide.

Package : 4ml/Amp x 5,20ml/Amp x 5

 
Glyact Tab. 200mg(Piogliazone HCL 200mg)

Composition : One tablet contains
Pioglitazone HCI - 200mg

Indication & Usage :
Treatment of type 2 diabetes mellitus inadequately controlled by diet

Dosage & Administration :

  • Once daily with or without food
  • Monotherapy : The recommended starting dosage is 15 mg once daily, if greater therapeutic effect is needed, to 30 mg once daily.

Package : 30 Tablets

B2B Trade

Price (FOB) Negotiable transportation -
MOQ Negotiable Leadtime Negotiable
Payment Options Negotiable Shipping time Negotiable

Myungmoon Pharm. Co., Ltd.

Country / Year Established
South Korea South Korea /
Business type
Others

16

TRADE TOWER

DUNS

President
LEE, GYU HUOK
Address
Myungmoon B/D, 946-18, Dokok-Dong, Gangnam-Ku, Korea
Product Category
Beauty & Personal Care,Chemical & Pharmaceutical Machinery,Pharmaceuticals
No. of Total Employees
101-500
Company introduction

In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation. Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.

Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.

Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, however, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future. To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.

Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.

Main Markets

China China

Main Product

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat A new message arrives
from a business partner.

No Data

  • There is no data to load
  • Check out the My tK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more